About: A rapidly adaptable biomaterial vaccine for SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A rapidly adaptable biomaterial vaccine for SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	A rapidly adaptable biomaterial vaccine for SARS-CoV-2
Creator	Yu, Jingyou Barouch, Dan John, Harvard Paulson, A Cartwright, Mark Doherty, Edward Langellotto, Fernanda Mooney, David Seiler, Benjamin Super, Michael White, Des Yeager, Chyenne
source	BioRxiv
abstract	The global COVID-19 pandemic motivates accelerated research to develop safe and efficacious vaccines. To address this need, we leveraged a biomaterial vaccine technology that consists of mesoporous silica rods (MSRs) that provide a sustained release of granulocyte-macrophage colony-stimulating factor (GM-CSF) and adjuvants to concentrate and mature antigen-presenting cells at the vaccine site. Here we explored the humoral responses resulting from the use of monophosphoryl lipid A (MPLA) as the adjuvant and SARS-CoV-2 spike proteins S1, S2, the nucleocapsid (N) protein, and receptor binding domain (RBD) as the target antigens. The dose of antigen and impact of pre-manufacturing of vaccines as versus loading antigen just-in-time was explored in these studies. Single shot MSR vaccines induced rapid and robust antibody titers to the presented antigens, even without the use of a boost, and sera from vaccinated animals demonstrated neutralizing activity against a SARS-CoV-2 pseudovirus. Overall, these results suggest the MSR vaccine system may provide potent protective immunity when utilized to present SARS-CoV-2 antigens.
has issue date	2020-07-07(xsd:dateTime)
bibo:doi	10.1101/2020.07.07.192203
has license	biorxiv
sha1sum (hex)	937d1ae9c0418d3428a6938eb91854e12b843176
schema:url	https://doi.org/10.1101/2020.07.07.192203
resource representing a document's title	A rapidly adaptable biomaterial vaccine for SARS-CoV-2
schema:publication	bioRxiv
resource representing a document's body	covid:937d1ae9c0418d3428a6938eb91854e12b843176#body_text
is schema:about of	named entity 'protein' named entity 'antigen' named entity 'vaccines' named entity 'RBD' named entity 'boost' named entity 'biomaterial' named entity 'MSR' named entity 'MPLA' named entity 'responses' named entity 'granulocyte-macrophage colony-stimulating factor' named entity 'pseudovirus' named entity 'antigens' named entity 'target' named entity 'consists' named entity 'address' named entity 'vaccinated' named entity 'animals' named entity 'activity' named entity 'induced' named entity 'COVID-19 pandemic' named entity 'antibody' named entity 'antigens' named entity 'spike proteins' named entity 'antigen-presenting cells' named entity 'humoral responses' named entity 'vaccine' named entity 'receptor binding domain' named entity 'antigens' named entity 'sustained release' named entity 'biomaterial' named entity 'antigen' named entity 'IgG' named entity 'antigen' named entity 'SARS-CoV-2' named entity 'reporter gene' named entity 'China' named entity 'epitope' named entity 'RBD' named entity 'antigen' named entity 'BioTek' named entity 'adjuvant' named entity 'SARS-CoV-2' named entity 'Severe Acute Respiratory Syndrome Coronavirus 2' named entity 'luciferase' named entity 'APCs' named entity 'global COVID-19 pandemic' named entity 'antibody' named entity 'Granulocyte-macrophage colony-stimulating factor' named entity 'causative agent' named entity 'antigens' named entity 'oncology' named entity 'tetraethyl orthosilicate' named entity 'antigen' named entity 'S protein' named entity 'adsorption' named entity 'respiratory tract disease' named entity 'angiotensin-converting enzyme 2' named entity 'SARS-CoV-2' named entity 'vaccine' named entity 'incubation' named entity 'immunization' named entity 'nucleocapsid' named entity 'protein subunit' named entity 'vaccine' named entity 'IgG' named entity 'lipid' named entity 'IgG antibody' named entity 'amorphous silica' named entity 'biomaterial' named entity 'mice' named entity 'SARS-CoV-2' named entity 'biomaterial' named entity 'antigen'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software